Large Scale Safety Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine, in Comparison to Tritanrix-Hep B/Hib and OPV Administered at 2, 4, and 6 Months of Age in Latin American Infants

Trial Profile

Large Scale Safety Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine, in Comparison to Tritanrix-Hep B/Hib and OPV Administered at 2, 4, and 6 Months of Age in Latin American Infants

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2014

At a glance

  • Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix); Poliovirus vaccine live oral
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Sanofi; sanofi pasteur
  • Most Recent Events

    • 19 Jan 2010 Actual end date added 1 Feb 2008 as reported by ClinicalTrials.gov.
    • 19 Jan 2010 Actual patient number (2133) added as reported by ClinicalTrials.gov.
    • 19 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top